Alliancebernstein L.P. Otonomy, Inc. Transaction History

Alliancebernstein L.P.

2 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q2 2018 Aug 13, 2018	SELL	$3.7 - $4.75 $112,110 - $143,925	-30,300 Closed	0 $0
Q3 2017 Nov 13, 2017	BUY	$3.2 - $20.8 $96,960 - $630,240	30,300	30,300 $98,000

Ticker OTIC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 56,990,400
Description
Otonomy, Inc., a biopharmaceutical company, develops therapeutics for neurotology in the United States. The company offers OTO-313, a sustained-exposure formulation of N-methyl-D-aspartate receptor antagonist gacyclidine, which is in Phase II clinical trials to treat tinnitus; and OTO-413, a sustained-exposure formulation of brain-derived neurot...

Get notified when there are updates to the investment portfolio of Alliancebernstein L.P., based on Form 13F filings with the SEC.

Stay updated on Alliancebernstein L.P. with notifications on news.